Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

Ohio: Cuts in Aid for HIV Drugs Bring New Set of Troubles

February 10, 2011

Cuts made last July to Ohio's AIDS Drug Assistance Program resulted in nearly 1,000 people being dropped off the rolls by December. Facing a $3.9 million deficit three months into the current fiscal year, ADAP instituted a waiting list, and eliminated altogether dental care, money for travel and medications unrelated to HIV.

Advertisement

Although the cuts and an infusion of federal money fixed last summer's dire financial situation, 390 Ohioans remain on the waiting list, the most recent figures from the National Alliance of State & Territorial AIDS Directors show. Jay Carey, management analyst for the state Ryan White program for low-income HIV/AIDS patients, says a recently awarded federal grant for $1.2 million will remove more than 100 additional people from the list.

Meanwhile, the Ohio Department of Health is working swiftly to change state rules to serve only ADAP's sickest patients. If instituted, the changes would eliminate some clients' assistance and cover the drugs of others who are currently waitlisted.

Clinics and drug companies have worked to ensure patients are getting medicines through sources other than ADAP, said Dr. John Davis, director of Ohio State University Medical Center's infectious-diseases clinic. However, Davis wonders "how long that is going to last." Columbus AIDS Task Force President Peggy Anderson said she does not know of anyone who has stopped HIV treatment since the cuts. Both Davis and Anderson worry that demands for assistance will overwhelm drugmakers, who are lobbying the federal government to provide more money to help state ADAPs.

In addition, Anderson is concerned about people who have switched medication for financial versus medical reasons. Side effects and potencies among HIV drugs vary, and changing them for reasons other than clinical ones is not ideal, she said.

Back to other news for February 2011

Adapted from:
Columbus Dispatch
02.06.2011; Misti Crane


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
2012 National ADAP Monitoring Project Annual Report: Module One (PDF)
After Five Years, ADAP Waiting Lists Have Been Eliminated; Unmet Need and Funding Uncertainties Require Continued Commitment
More on ADAP Restrictions and Waiting Lists

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement